Genetically engineered mouse models in oncology research and cancer medicine
Open accessThe DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Genetically engineered mouse models (GEMMs) have contributed significantly to the field of cancer research. In contrast to cancer cell inoculation models, GEMMs develop de novo tumors in a natural immune‐proficient microenvironment. Tumors arising in advanced GEMMs closely mimic the histopathological and molecular features of their human counterparts, display genetic heterogeneity, and are able to spontaneously progress toward metastatic disease. As such, GEMMs are generally superior to cancer cell inoculation models, which show no or limited heterogeneity and are often metastatic from the start. Given that GEMMs capture both tumor cell‐intrinsic and cell‐extrinsic factors that drive de novo tumor initiation and progression toward metastatic disease, these models are indispensable for preclinical research. GEMMs have successfully been used to validate candidate cancer genes and drug targets, assess therapy efficacy, dissect the impact of the tumor microenvironment, and evaluate mechanisms of drug resistance. In vivo validation of candidate cancer genes and therapeutic targets is further accelerated by recent advances in genetic engineering that enable fast‐track generation and fine‐tuning of GEMMs to more closely resemble human patients. In addition, aligning preclinical tumor intervention studies in advanced GEMMs with clinical studies in patients is expected to accelerate the development of novel therapeutic strategies and their translation into the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a tumor will be cultivated in vivo within these animals, it is also able to better mimic the molecular and histopathological features of cancer [40,41].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“GEMMs are powerful tools for studying the pathogenesis of cancer and examining the systemic effects of vitamin C in vivo113.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339 · cited 2×
“These approaches have now been outperformed by the development of CRISPR/Cas9 systems for genome editing (Cong et al , 2013), which have revolutionized biological research over the past 3 years and are considered the biggest game changer since PCR.”
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“…in patients with advanced melanoma and lung cancer confirm the remarkable potential of immune checkpoint blockade, including anti-CTLA-4 and anti-PD-1, to enhance effective anti-tumor immunity and to improve survival in a proportion of the patients (Hodi et al , 2010; Topalian et al , 2012, 1).”
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“…in patients with advanced melanoma and lung cancer confirm the remarkable potential of immune checkpoint blockade, including anti-CTLA-4 and anti-PD-1, to enhance effective anti-tumor immunity and to improve survival in a proportion of the patients (Hodi et al , 2010; Topalian et al , 2012, 1).”
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 1×
“The metastatic cascade is a complex multi-step process managed by a constant crosstalk between cancer cells and their microenvironment (Quail & Joyce, 2013; McAllister & Weinberg, 2014).”
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“However, even though durable responses are observed in some cases, a large proportion of cancer patients does not show clinical benefit (Sharma & Allison, 2015).”
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 3×
“Genetic studies in GEMMs with reversible inactivation of p53 have shown that restoration of p53 leads to rapid regression of established tumors (Martins et al , 2006; Ventura et al , 2007; Xue et al , 2007), providing strong rationale for designing anti-cancer drugs that restore p53 function by inhibiting MDM2 (Vassil…”
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“Moreover, fibroblasts are a source of various soluble mediators including matrix metalloproteinases (MMPs), which enable ECM turnover, reinforcing their crucial role in maintaining ECM homeostasis (Kalluri & Zeisberg, 2006).”
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · cited 1×
“Since then the tumor-promoting roles of inflammation-induced tumor-associated macrophages (TAMs) (Lin et al , 2001; Noy & Pollard, 2014) and neutrophils (Jamieson et al , 2012; Bald et al , 2014; Coffelt et al , 2015, 2016; Wculek & Malanchi, 2015) have been described in several studies.”
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 2×
“Furthermore, many of the fundamental insights into anti-tumor immunity, T-cell tolerance mechanisms, and immune-escape routes of tumors come from in vivo studies with cell line allograft models (Leach et al , 1996).”
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696 · cited 1×
“The CRISPR/Cas9 system has recently been modified to induce target gene repression (CRISPRi) or activation (CRISPRa) (Gilbert et al , 2013).”
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495 · cited 2×
“…genetic alterations found in human tumors can now be rapidly introduced in the mouse germline, including (conditional) gene deletions (Wang et al , 2013; Yang et al , 2013), point mutations (Wang et al , 2013), and translocations (Blasco et al , 2014; Choi & Meyerson, 2014; Torres et al , 2014).”
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · cited 1×
“This is illustrated by tumor intervention studies in a GEMM of PDAC, which showed that therapeutic inhibition of paracrine Sonic Hedgehog (SHH) signaling reduced desmoplastic tumor stroma and increased tumor vasculature, resulting in enhanced delivery of gemcitabine to tumors (Olive et al , 2009).”
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922 · cited 1×
“Moreover, xenograft studies identified distinct gene expression signatures that mediate organ-specific patterns of metastatic colonization (Kang et al , 2003; Minn et al , 2005; Bos et al , 2009).”
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 2×
“The basis of these clinical trials comes from several decades of fundamental research in experimental mouse models that have revealed the importance of CTLA-4 and PD-1 in restraining immune responses, as most clearly illustrated by the severe sponta-neous autoimmunity phenotype in CTLA-4-deficient (Waterhouse et al ,…”
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“…models that have revealed the importance of CTLA-4 and PD-1 in restraining immune responses, as most clearly illustrated by the severe sponta-neous autoimmunity phenotype in CTLA-4-deficient (Waterhouse et al , 1995) and to a milder extent in PD-1-deficient mice (Nishimura et al , 1999, 2001).”
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,597 · cited 2×
“Here, we give an overview of mouse models that are most commonly used in cancer research.”
Transcriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488 · cited 1×
“Also systems for doxycycline-regulatable gene expression have been successfully used in GEMMs to turn oncogenes on to induce tumorigenesis; and off to determine how established tumors respond to oncogene inactivation (Gossen et al , 1995; Lewandoski, 2001).”
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“…inactivation of p53 have shown that restoration of p53 leads to rapid regression of established tumors (Martins et al , 2006; Ventura et al , 2007; Xue et al , 2007), providing strong rationale for designing anti-cancer drugs that restore p53 function by inhibiting MDM2 (Vassilev et al , 2004) or…”
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430 · cited 1×
“The link between inflammation and cancer has been demonstrated in mouse models of several different cancer types (Greten et al , 2004; Pikarsky et al , 2004; DeNardo et al , 2009; Guerra et al , 2011; Jamieson et al , 2012; Pyonteck et al , Bald et al , 2014; Coffelt et al , 2015; Wculek &…”
Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987) · Journal of Bacteriology · doi:10.1128/jb.169.12.5429-5433.1987 · Cited by 2,421 · cited 1×
“…regularly interspaced short palindromic repeats)/Cas9 system was first discovered as a prokaryotic immune system that confers resistance to foreign genetic elements, but soon thereafter has been exploited to achieve gene editing (Ishino et al , 1987; Mojica et al , 2000; Jansen et al , 2002).”
Breast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232 · cited 1×
“Another major challenge is metastatic disease, which accounts for over ninety percent of cancer-related deaths (Weigelt et al , 2005).”
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085 · cited 1×
“However, the concept of targeting tumor stroma in PDAC has recently been challenged by two studies showing that stromal factors may suppress rather than promote PDAC growth, possibly by restraining tumor angiogenesis (O¨zdemir et al , 2014; Rhim et al , 2014).”
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · cited 3×
“The results of this study led to the initiation of a clinical trial in which CRC patients were treated with a combination therapy targeting both BRAF V600E and EGFR (Prahallad et al , 2012), illustrating the usefulness of xenotransplantation models in establishing novel combinatorial treatment strategies.”
Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032 · cited 1×
“However, recent studies in GEMMs of pancreatic and breast cancer show that cancer cells retain their epithelial characteristics while colonizing metastatic sites, suggesting that EMT is not essential for metastasis formation in these models (Fischer et al , 2015; Zheng et al , 2015).”
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001 · cited 1×
“These efforts have led to a new generation of non-germline models of hepatocellular carcinoma (Xue et al , 2014; Weber et al , 2015), lung cancer (Platt et al , 2014; Sa´nchez-Rivera et al , 2014), brain cancer (Zuckermann et al , 2015), pancreatic cancer (Chiou et al , 2015; Maresch et al , 2016),…”
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883 · cited 2×
“Based on promising results obtained in clinical trials (Ledermann et al , 2012, 2014), olaparib (trade name LynParza) was approved by the FDA in December 2014 for the treatment of patients with advanced BRCA1 / 2 -mutated ovarian cancer.”
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868 · cited 1×
“…models that have revealed the importance of CTLA-4 and PD-1 in restraining immune responses, as most clearly illustrated by the severe sponta-neous autoimmunity phenotype in CTLA-4-deficient (Waterhouse et al , 1995) and to a milder extent in PD-1-deficient mice (Nishimura et al , 1999, 2001).”
Genes that mediate breast cancer metastasis to the brain
Bos, P. D., Zhang, X. H.-F., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., Minn, A. J., van de Vijver, M. J., Gerald, W. L., Foekens, J. A., et al. (2009) · Nature · doi:10.1038/nature08021 · Cited by 1,863 · cited 1×
“Moreover, xenograft studies identified distinct gene expression signatures that mediate organ-specific patterns of metastatic colonization (Kang et al , 2003; Minn et al , 2005; Bos et al , 2009).”
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830 · cited 1×
“Since then the tumor-promoting roles of inflammation-induced tumor-associated macrophages (TAMs) (Lin et al , 2001; Noy & Pollard, 2014) and neutrophils (Jamieson et al , 2012; Bald et al , 2014; Coffelt et al , 2015, 2016; Wculek & Malanchi, 2015) have been described in several studies.”
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“…GEMMs with reversible inactivation of p53 have shown that restoration of p53 leads to rapid regression of established tumors (Martins et al , 2006; Ventura et al , 2007; Xue et al , 2007), providing strong rationale for designing anti-cancer drugs that restore p53 function by inhibiting MDM2…”
Identification of genes that are associated with DNA repeats in prokaryotes
Jansen, R., Embden, J. D. A. V., Gaastra, W., & Schouls, L. M. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02839.x · Cited by 1,802 · cited 1×
“…regularly interspaced short palindromic repeats)/Cas9 system was first discovered as a prokaryotic immune system that confers resistance to foreign genetic elements, but soon thereafter has been exploited to achieve gene editing (Ishino et al , 1987; Mojica et al , 2000; Jansen et al , 2002).”
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791 · cited 1×
“However, recent studies in GEMMs of pancreatic and breast cancer show that cancer cells retain their epithelial characteristics while colonizing metastatic sites, suggesting that EMT is not essential for metastasis formation in these models (Fischer et al , 2015; Zheng et al , 2015).”
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742 · cited 1×
“Unlike cell line transplantation models, PDTX tumors maintain the molecular, genetic, and histological heterogeneity as observed in cancer patients, even after serial passaging in mice (Hidalgo et al , 2014).”
Self-citationDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“…clear that therapy response and resistance is not only influenced by tumor cell-intrinsic factors but also by stromal factors such as fibroblasts and immune cells (Farmer et al , 2009; DeNardo et al , 2011; Shree et al , 2011; Acharyya et al , 2012; Nakasone et al , 2012; Boelens et al , 2014).”
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703 · cited 5×
“…between inflammation and cancer has been demonstrated in mouse models of several different cancer types (Greten et al , 2004; Pikarsky et al , 2004; DeNardo et al , 2009; Guerra et al , 2011; Jamieson et al , 2012; Pyonteck et al , Bald et al , 2014; Coffelt et al , 2015; Wculek & Malanchi, 2015).”
InfluentialSelf-citationYang, H., Wang, H., Shivalila, C. S., Cheng, A. W., Shi, L., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.022 · Cited by 1,596 · cited 1×
“…genetic alterations found in human tumors can now be rapidly introduced in the mouse germline, including (conditional) gene deletions (Wang et al , 2013; Yang et al , 2013), point mutations (Wang et al , 2013), and translocations (Blasco et al , 2014; Choi & Meyerson, 2014; Torres et al , 2014).”
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594 · cited 3×
“For example, genetic ablation of colony-stimulating factor 1 (CSF1), an important factor for macrophages, in the MMTV-PyMT breast cancer mouse model delayed progression of mammary tumors to malignancy (Lin et al , 2001).”
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515 · cited 1×
“During malignant transformation of epithelial cells, CAFs can stimulate tumor progression by enhancing inflammation, angiogenesis, and ECM remodeling, as was demonstrated in the K14-HPV16 squamous skin cancer model (Erez et al , 2010).”
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442 · cited 2×
“Based on promising results obtained in clinical trials (Ledermann et al , 2012, 2014), olaparib (trade name LynParza) was approved by the FDA in December 2014 for the treatment of patients with advanced BRCA1 / 2 -mutated ovarian cancer.”
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393 · cited 2×
“Cancer-associated fibroblasts (CAFs) Fibroblasts that reside in the tumor microenvironment.”
DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., & Coussens, L. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.018 · Cited by 1,353 · cited 2×
“Several laboratories have shown that myeloid immune cells, such as macrophages and neutrophils, play key roles in promoting metastasis formation in different types of cancer (Lin et al , 2001; DeNardo et al , 2009; Bald et al , 2014; Coffelt et al , 2015; Wculek & Malanchi, 2015).”
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 1×
“Compared to Trp53 knockouts, patient-relevant Trp53 hotspot mutations in mice were shown to have enhanced oncogenic activity (Lang et al , 2004; Olive et al , 2004).”
MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis
Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000) · Cell · doi:10.1016/s0092-8674(00)00139-2 · Cited by 1,306
Hanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,201 · cited 1×
“Recent studies have demonstrated that boosting dendritic cell function (Broz et al , 2014; Ruffell et al , 2014; Salmon et al , 2016; Sa ´ nchez-Paulete et al , 2016) or blocking myeloid cell-induced immunosuppression (Highfill et al , 2014; Zhu et al , 2014) improves the anti-tumor efficacy of…”
Systemic Spread Is an Early Step in Breast Cancer
Hüsemann, Y., Geigl, J. B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., Forni, G., Eils, R., Fehm, T., Riethmüller, G., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.003 · Cited by 1,188 · cited 1×
“However, studies in BALB-NeuT and MMTV-PyMT mouse mammary tumor models revealed that transformed cells in early lesions are already capable of disseminating to bone marrow and lungs, and form micro-metastasis (Hu¨semann et al , 2008).”
The perivascular niche regulates breast tumour dormancy
Ghajar, C. M., Peinado, H., Mori, H., Matei, I. R., Evason, K. J., Brazier, H., Almeida, D., Koller, A., Hajjar, K. A., Stainier, D. Y. R., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2767 · Cited by 1,148 · cited 1×
“In addition, these models revealed that disseminated breast cancer cells reside adjacent to blood vessels, which might provide a niche regulating dormancy of disseminated cancer cells (Ghajar et al , 2013).”
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085 · cited 1×
“…clear that therapy response and resistance is not only influenced by tumor cell-intrinsic factors but also by stromal factors such as fibroblasts and immune cells (Farmer et al , 2009; DeNardo et al , 2011; Shree et al , 2011; Acharyya et al , 2012; Nakasone et al , 2012; Boelens et al , 2014).”
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 1×
“Compared to Trp53 knockouts, patient-relevant Trp53 hotspot mutations in mice were shown to have enhanced oncogenic activity (Lang et al , 2004; Olive et al , 2004).”
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 1×
“…regression of established tumors (Martins et al , 2006; Ventura et al , 2007; Xue et al , 2007), providing strong rationale for designing anti-cancer drugs that restore p53 function by inhibiting MDM2 (Vassilev et al , 2004) or by restoring wild-type function to mutant p53 (Bykov et al , 2002).”
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008 · cited 2×
“Recent studies have demonstrated that boosting dendritic cell function (Broz et al , 2014; Ruffell et al , 2014; Salmon et al , 2016; Sa ´ nchez-Paulete et al , 2016) or blocking myeloid cell-induced immunosuppression (Highfill et al , 2014; Zhu et al , 2014) improves the anti-tumor efficacy of…”
Neutrophils support lung colonization of metastasis-initiating breast cancer cells
Wculek, S. K., & Malanchi, I. (2015) · Nature · doi:10.1038/nature16140 · Cited by 1,003 · cited 3×
“Several laboratories have shown that myeloid immune cells, such as macrophages and neutrophils, play key roles in promoting metastasis formation in different types of cancer (Lin et al , 2001; DeNardo et al , 2009; Bald et al , 2014; Coffelt et al , 2015; Wculek & Malanchi, 2015).”
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
McAllister, S. S., & Weinberg, R. A. (2014) · Nature Cell Biology · doi:10.1038/ncb3015 · Cited by 966 · cited 1×
“The metastatic cascade is a complex multi-step process managed by a constant crosstalk between cancer cells and their microenvironment (Quail & Joyce, 2013; McAllister & Weinberg, 2014).”
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956 · cited 2×
“Preclinical studies in KB1P mice revealed several mechanisms of resistance, such as elevated levels of drug efflux transporters and restoration of homologous recombination (Rottenberg et al , 2008; Jaspers et al , 2013; Henneman et al , 2015; Xu et al , 2015).”
Self-citationInflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G. H., & Hanahan, D. (1999) · Genes & Development · doi:10.1101/gad.13.11.1382 · Cited by 946 · cited 1×
“More-over, studies in the K14-HPV16 model have shown that mast cells and bone marrow-derived cells promote squamous skin cancer by activating angiogenesis and by reorganizing stromal architecture via MMP9 (Coussens et al , 1999, 2000).”
Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943 · cited 1×
“Tumors are often characterized by chronic inflammation, which induces local and systemic immunosuppression that is unfavorable for T cells to perform their effector function (Mitchem et al , 2013; Ruffell et al , 2014; Coffelt et al , 2015).”
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 2×
“Cancer-associated fibroblasts (CAFs) Fibroblasts that reside in the tumor microenvironment.”
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Lawson, D. A., Bhakta, N. R., Kessenbrock, K., Prummel, K. D., Yu, Y., Takai, K., Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.-Y., et al. (2015) · Nature · doi:10.1038/nature15260 · Cited by 893
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881 · cited 1×
“For example, continuous expression of a doxycycline-inducible Myc transgene in hematopoietic cells resulted in the formation of malignant T-cell lymphomas and acute myeloid leukemia that regressed upon de-induction of expression (Felsher & Bishop, 1999).”
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874 · cited 1×
“In contrast, invasive liver cancers regressed after MYC inactivation, but residual tumor cells remained dormant and immediately restored their neoplastic features upon MYC reactivation (Shachaf et al , 2004).”
Mojica, F. J. M., Díez‐Villaseñor, C., Soria, E., & Juez, G. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.01838.x · Cited by 820 · cited 1×
“…regularly interspaced short palindromic repeats)/Cas9 system was first discovered as a prokaryotic immune system that confers resistance to foreign genetic elements, but soon thereafter has been exploited to achieve gene editing (Ishino et al , 1987; Mojica et al , 2000; Jansen et al , 2002).”
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
Boelens, M. C., Wu, T. J., Nabet, B. Y., Xu, B., Qiu, Y., Yoon, T., Azzam, D. J., Twyman-Saint Victor, C., Wiemann, B. Z., Ishwaran, H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.051 · Cited by 806 · cited 1×
“…clear that therapy response and resistance is not only influenced by tumor cell-intrinsic factors but also by stromal factors such as fibroblasts and immune cells (Farmer et al , 2009; DeNardo et al , 2011; Shree et al , 2011; Acharyya et al , 2012; Nakasone et al , 2012; Boelens et al , 2014).”
Self-citationMolyneux, G., Geyer, F. C., Magnay, F.-A., McCarthy, A., Kendrick, H., Natrajan, R., MacKay, A., Grigoriadis, A., Tutt, A., Ashworth, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.010 · Cited by 794 · cited 1×
“While BRCA1-related basal-like breast cancer was previously postulated to originate from basal epithelial stem cells, cell-of-origin studies in GEMMs revealed that in fact, luminal progenitors are the source of basal-like tumors (Molyneux et al , 2010).”
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792 · cited 2×
“The first oncomouse was a GEMM with transgenic expression of a specific activated oncogene ( v-HRas ) under control of a mammary-specific promoter ( MMTV ), making the mouse prone to developing mammary tumors (Sinn et al , 1987).”
Conditional control of gene expression in the mouse
Lewandoski, M. (2001) · Nature Reviews Genetics · doi:10.1038/35093537 · Cited by 781 · cited 2×
“Also systems for doxycycline-regulatable gene expression have been successfully used in GEMMs to turn oncogenes on to induce tumorigenesis; and off to determine how established tumors respond to oncogene inactivation (Gossen et al , 1995; Lewandoski, 2001).”
CRISPR-mediated direct mutation of cancer genes in the mouse liver
Xue, W., Chen, S., Yin, H., Tammela, T., Papagiannakopoulos, T., Joshi, N. S., Cai, W., Yang, G., Bronson, R., Crowley, D. G., et al. (2014) · Nature · doi:10.1038/nature13589 · Cited by 776 · cited 1×
“These efforts have led to a new generation of non-germline models of hepatocellular carcinoma (Xue et al , 2014; Weber et al , 2015), lung cancer (Platt et al , 2014; Sa´nchez-Rivera et al , 2014), brain cancer (Zuckermann et al , 2015), pancreatic cancer (Chiou et al , 2015; Maresch et al , 2016),…”
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767 · cited 1×
“…that boosting dendritic cell function (Broz et al , 2014; Ruffell et al , 2014; Salmon et al , 2016; Sa ´ nchez-Paulete et al , 2016) or blocking myeloid cell-induced immunosuppression (Highfill et al , 2014; Zhu et al , 2014) improves the anti-tumor efficacy of immune checkpoint blockade.”
Maximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717 · cited 1×
“By introducing mutations associated with a specific type of cancer, one can generate mouse models that closely mimic the histopathological, molecular, and clinical features of tumors in patients (Frese & Tuveson, 2007; Walrath et al , 2010).”
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.014 · Cited by 715 · cited 1×
“Using the same skin cancer model, chronic inflammation was found to promote de novo carcinogenesis in a B lymphocyte-dependent manner (de Visser et al , 2005).”
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Hodgkinson, C. L., Morrow, C. J., Li, Y., Metcalf, R. L., Rothwell, D. G., Trapani, F., Polanski, R., Burt, D. J., Simpson, K. L., Morris, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3600 · Cited by 694 · cited 1×
“For small-cell lung cancer (SCLC), it was shown that circulating tumor cells (CTCs) from blood can be used to establish CTC-derived explant (CDX) models that mirror the donor patient’s response to platinum and etoposide (Hodgkinson et al , 2014).”
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657 · cited 1×
“…2011), breast cancer (Marangoni et al , 2007), melanoma (Kemper et al , 2015; Girotti et al , 2016), prostate cancer (Yoshida et al , 2005; Qu et al , 2014), and colorectal cancer (Bertotti et al , 2011, 2015; Bardelli et al , 2013; Kavuri et al , 2015; Misale et al , 2015; Zanella et al , 2015).”
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 644 · cited 1×
“For example, brief inactivation of MYC in osteogenic sarcomas resulted in sustained regression due to differentiation of sarcoma cells into mature osteocytes (Jain et al , 2002).”
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., et al. (2014) · Nature · doi:10.1038/nature13902 · Cited by 640 · cited 1×
“Besides modifying TSGs, CRISPR/Cas9 technology can be applied to validate the onco-genicity of chromosomal rearrangements, such as the Eml4-Alk gene fusion observed in lung cancer (Maddalo et al , 2014).”
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma
Bald, T., Quast, T., Landsberg, J., Rogava, M., Glodde, N., Lopez-Ramos, D., Kohlmeyer, J., Riesenberg, S., van den Boorn-Konijnenberg, D., Hömig-Hölzel, C., et al. (2014) · Nature · doi:10.1038/nature13111 · Cited by 623 · cited 3×
“Several laboratories have shown that myeloid immune cells, such as macrophages and neutrophils, play key roles in promoting metastasis formation in different types of cancer (Lin et al , 2001; DeNardo et al , 2009; Bald et al , 2014; Coffelt et al , 2015; Wculek & Malanchi, 2015).”
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Farmer, P., Bonnefoi, H., Anderle, P., Cameron, D., Wirapati, P., Becette, V., André, S., Piccart, M., Campone, M., Brain, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.1908 · Cited by 623 · cited 1×
“…clear that therapy response and resistance is not only influenced by tumor cell-intrinsic factors but also by stromal factors such as fibroblasts and immune cells (Farmer et al , 2009; DeNardo et al , 2011; Shree et al , 2011; Acharyya et al , 2012; Nakasone et al , 2012; Boelens et al , 2014).”
Rapid Colorectal Adenoma Formation Initiated by Conditional Targeting of the Apc Gene
Shibata, H., Toyama, K., Shioya, H., Ito, M., Hirota, M., Hasegawa, S., Matsumoto, H., Takano, H., Akiyama, T., Toyoshima, K., et al. (1997) · Science · doi:10.1126/science.278.5335.120 · Cited by 605 · cited 1×
“APC loss in intestinal epithelial cells was sporadically induced through adenovirus-mediated delivery of Cre-recombinase, resulting in the rapid onset of colorectal adenomas that shared many features with adenomas in familial adenomatous polyposis coli (FAP) patients (Shibata et al , 1997).”
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 2×
“…models to determine oncogene addiction, as the genetic lesion is irreversible, and thus requires another layer of alleles are replaced by a tamoxifen-inducible Trp53-ERT variant and were used to determine the therapeutic efficacy of p53 restoration in established tumors (Martins et al , 2006).”
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Xu, G., Chapman, J. R., Brandsma, I., Yuan, J., Mistrik, M., Bouwman, P., Bartkova, J., Gogola, E., Warmerdam, D., Barazas, M., et al. (2015) · Nature · doi:10.1038/nature14328 · Cited by 593 · cited 1×
“Preclinical studies in KB1P mice revealed several mechanisms of resistance, such as elevated levels of drug efflux transporters and restoration of homologous recombination (Rottenberg et al , 2008; Jaspers et al , 2013; Henneman et al , 2015; Xu et al , 2015).”
Self-citationDow, L. E., O’Rourke, K. P., Simon, J., Tschaharganeh, D. F., van Es, J. H., Clevers, H., & Lowe, S. W. (2015) · Cell · doi:10.1016/j.cell.2015.05.033 · Cited by 552 · cited 9×
“Finally, CRISPR/Cas9-mediated genome editing may create unwanted off-target mutations that may be circumvented by employing pairs of sgRNAs in mice with inducible expression of a Cas9n “nickase” variant that induces DNA single-strand breaks (Dow et al , 2015a).”
InfluentialGenerating genetically modified mice using CRISPR/Cas-mediated genome engineering
Yang, H., Wang, H., & Jaenisch, R. (2014) · Nature Protocols · doi:10.1038/nprot.2014.134 · Cited by 551 · cited 1×
“The CRISPR/Cas9 system can also be used to introduce defined mutations or loxP / FRT recombination sites, by simply co-introducing oligonucleotides that can serve as a template for repair of the Cas9-induced break (Yang et al , 2014).”
In vivo genome editing restores haemostasis in a mouse model of haemophilia
Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., Malani, N., Anguela, X. M., Sharma, R., Ivanciu, L., et al. (2011) · Nature · doi:10.1038/nature10177 · Cited by 548 · cited 1×
“…the latter approach, Dow et al Genome editing using CRISPR/Cas 9 technology In the past decades, additional approaches for genome editing have been developed such as Zinc-finger nucleases (ZFNs) and transcrip-tion-activator-like effector nucleases (TALENs) (Li et al , 2011; Wefers et al , 2013).”
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541 · cited 1×
“…clear that therapy response and resistance is not only influenced by tumor cell-intrinsic factors but also by stromal factors such as fibroblasts and immune cells (Farmer et al , 2009; DeNardo et al , 2011; Shree et al , 2011; Acharyya et al , 2012; Nakasone et al , 2012; Boelens et al , 2014).”
Sutherland, K. D., Proost, N., Brouns, I., Adriaensen, D., Song, J.-Y., & Berns, A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.019 · Cited by 534 · cited 5×
“Similarly, co-clinical trials in GEMMs of NSCLC showed that Kras / Lkb1 -mutant lung tumors are more resistant to combination therapy with docetaxel and the MEK inhibitor selumetinib than Kras - or Kras / p53 -mutant tumors, highlighting LKB1 as a potential determinant of resistance in clinical trials with this combin…”
InfluentialExpression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529 · cited 1×
“For example, the introduction of tumor-specific antigens in GEMMs with low immunogenic tumors, such as sarcomas and lung cancer, increased the immunogenicity of these tumors and resulted in a potent, but transient, anti-tumor T-cell response (DuPage et al , 2011, 2012).”
Joshi, N. S., Akama-Garren, E. H., Lu, Y., Lee, D.-Y., Chang, G. P., Li, A., DuPage, M., Tammela, T., Kerper, N. R., Farago, A. F., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.006 · Cited by 520 · cited 1×
“The initial anti-tumor T-cell response was quickly followed by regulatory T-cell-mediated immunosuppression (Joshi et al , 2015).”
Guerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernández-Porras, I., Cañamero, M., Rodriguez-Justo, M., Serrano, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.011 · Cited by 516 · cited 1×
“…between inflammation and cancer has been demonstrated in mouse models of several different cancer types (Greten et al , 2004; Pikarsky et al , 2004; DeNardo et al , 2009; Guerra et al , 2011; Jamieson et al , 2012; Pyonteck et al , Bald et al , 2014; Coffelt et al , 2015; Wculek & Malanchi, 2015).”
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514 · cited 1×
“Preclinical studies in KB1P mice revealed several mechanisms of resistance, such as elevated levels of drug efflux transporters and restoration of homologous recombination (Rottenberg et al , 2008; Jaspers et al , 2013; Henneman et al , 2015; Xu et al , 2015).”
Self-citationInducible in vivo genome editing with CRISPR-Cas9
Dow, L. E., Fisher, J., O'Rourke, K. P., Muley, A., Kastenhuber, E. R., Livshits, G., Tschaharganeh, D. F., Socci, N. D., & Lowe, S. W. (2015) · Nature Biotechnology · doi:10.1038/nbt.3155 · Cited by 488 · cited 9×
“Finally, CRISPR/Cas9-mediated genome editing may create unwanted off-target mutations that may be circumvented by employing pairs of sgRNAs in mice with inducible expression of a Cas9n “nickase” variant that induces DNA single-strand breaks (Dow et al , 2015a).”
InfluentialSánchez-Paulete, A. R., Cueto, F. J., Martínez-López, M., Labiano, S., Morales-Kastresana, A., Rodríguez-Ruiz, M. E., Jure-Kunkel, M., Azpilikueta, A., Aznar, M. A., Quetglas, J. I., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0510 · Cited by 484
Transgenic mice harboring SV40 t-antigen genes develop characteristic brain tumors
Brinster, R. L., Chen, H. Y., Messing, A., van Dyke, T., Levine, A. J., & Palmiter, R. D. (1984) · Cell · doi:10.1016/0092-8674(84)90367-2 · Cited by 483 · cited 1×
“…first oncomice led to great excitement in the cancer research community as they provided unambiguous proof for the hypothesis that oncogene expression in normal cells could lead to tumor formation (Brinster et al , 1984; Hanahan, 1985; Lacey et al , 1986; Sinn et al , 1987; Ru¨ther et al , 1989).”
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479 · cited 1×
“…2011), breast cancer (Marangoni et al , 2007), melanoma (Kemper et al , 2015; Girotti et al , 2016), prostate cancer (Yoshida et al , 2005; Qu et al , 2014), and colorectal cancer (Bertotti et al , 2011, 2015; Bardelli et al , 2013; Kavuri et al , 2015; Misale et al , 2015; Zanella et al , 2015).”
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 478 · cited 1×
“…clear that therapy response and resistance is not only influenced by tumor cell-intrinsic factors but also by stromal factors such as fibroblasts and immune cells (Farmer et al , 2009; DeNardo et al , 2011; Shree et al , 2011; Acharyya et al , 2012; Nakasone et al , 2012; Boelens et al , 2014).”
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 1×
“…that Kras / Lkb1 -mutant lung tumors are more resistant to combination therapy with docetaxel and the MEK inhibitor selumetinib than Kras - or Kras / p53 -mutant tumors, highlighting LKB1 as a potential determinant of resistance in clinical trials with this combination therapy (Chen et al , 2012).”
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Willimsky, G., & Blankenstein, T. (2005) · Nature · doi:10.1038/nature03954 · Cited by 445 · cited 2×
“…transplantation of GEMM-derived tumor cells in immunodeficient mice resulted in rapid tumor growth, while wild-type mice rejected these tumors (Willimsky & Blankenstein, 2005; Garbe et al , 2006; DuPage et al , 2011), demonstrating that the cancer cells did not lose their immunogenicity and T…”
An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer
Zender, L., Xue, W., Zuber, J., Semighini, C. P., Krasnitz, A., Ma, B., Zender, P., Kubicka, S., Luk, J. M., Schirmacher, P., et al. (2008) · Cell · doi:10.1016/j.cell.2008.09.061 · Cited by 428 · cited 1×
“…vivo RNAi screens have been successfully used to identify novel TSGs in mouse models of hepatocellular carcinoma and lymphoma (Hemann et al , 2003; Zender et al , 2008; Bric et al , 2009), and to identify genes involved in resistance to the tyrosine kinase inhibitor sorafenib in liver cancer…”
A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays
Marangoni, E., Vincent-Salomon, A., Auger, N., Degeorges, A., Assayag, F., de Cremoux, P., de Plater, L., Guyader, C., De Pinieux, G., Judde, J.-G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0078 · Cited by 422 · cited 1×
“…by preclinical drug screening in PDTX models of non-small-cell lung cancer (NSCLC) (Fichtner et al , 2008; Merk et al , 2009, 2011), breast cancer (Marangoni et al , 2007), melanoma (Kemper et al , 2015; Girotti et al , 2016), prostate cancer (Yoshida et al , 2005; Qu et al , 2014), and…”
Rapid modelling of cooperating genetic events in cancer through somatic genome editing
Sánchez-Rivera, F. J., Papagiannakopoulos, T., Romero, R., Tammela, T., Bauer, M. R., Bhutkar, A., Joshi, N. S., Subbaraj, L., Bronson, R. T., Xue, W., et al. (2014) · Nature · doi:10.1038/nature13906 · Cited by 407 · cited 1×
“…led to a new generation of non-germline models of hepatocellular carcinoma (Xue et al , 2014; Weber et al , 2015), lung cancer (Platt et al , 2014; Sa´nchez-Rivera et al , 2014), brain cancer (Zuckermann et al , 2015), pancreatic cancer (Chiou et al , 2015; Maresch et al , 2016), and breast…”
Applications of the CRISPR-Cas9 system in cancer biology
Sánchez-Rivera, F. J., & Jacks, T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3950 · Cited by 405 · cited 1×
“CRISPR/Cas9 technology seems the system of choice for rapid cancer modeling in mice, as it has proven to be an efficient gene-targeting strategy with the potential for multiplexed genome editing (Sa´nchez-Rivera & Jacks, 2015).”
Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis
Jamieson, T., Clarke, M., Steele, C. W., Samuel, M. S., Neumann, J., Jung, A., Huels, D., Olson, M. F., Das, S., Nibbs, R. J. B., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61067 · Cited by 391 · cited 3×
“Similarly, inhibition of CXCR2, a mediator of neutrophil-migration, suppressed the formation of intestinal tumors in APC min /+ mice (Jamieson et al , 2012).”
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity
Van Keymeulen, A., Lee, M. Y., Ousset, M., Brohée, S., Rorive, S., Giraddi, R. R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I., et al. (2015) · Nature · doi:10.1038/nature14665 · Cited by 354 · cited 1×
“Expression of Pik3ca H1047R was shown to evoke dedifferentiation of lineage-committed mammary epithelial cells into a multipotent stem - like state (Koren et al , 2015; Van Keymeulen et al , 2015).”
Hemann, M. T., Fridman, J. S., Zilfou, J. T., Hernando, E., Paddison, P. J., Cordon-Cardo, C., Hannon, G. J., & Lowe, S. W. (2003) · Nature Genetics · doi:10.1038/ng1091 · Cited by 354 · cited 1×
“In vivo RNAi screens have been successfully used to identify novel TSGs in mouse models of hepatocellular carcinoma and lymphoma (Hemann et al , 2003; Zender et al , 2008; Bric et al , 2009), and to identify genes involved in resistance to the tyrosine kinase inhibitor sorafenib in liver cancer…”
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 352
Vooijs, M., Jonkers, J., & Berns, A. (2001) · EMBO reports · doi:10.1093/embo-reports/kve064 · Cited by 352 · cited 1×
“Hence, mice with (tissue-specific) expression of Cre-ERT allow for spatiotemporally controlled Cre-mediated genomic recombination upon administration of tamoxifen (Vooijs et al , 2001).”
Self-citationWang, D., Mou, H., Li, S., Li, Y., Hough, S., Tran, K., Li, J., Yin, H., Anderson, D. G., Sontheimer, E. J., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.087 · Cited by 345 · cited 1×
“Moreover, somatic delivery of Cas9 may trigger Cas9-specific immune responses resulting in clearance of Cas9-expressing cells (Wang et al , 2015; Annunziato et al , 2016).”
Engelhardt, J. J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., & Krummel, M. F. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.008 · Cited by 330 · cited 1×
“For example, MMTV-PyMT mammary tumors display dendritic cells that are potent activators of anti-tumor T cells, but these cells are outcompeted by the overabundant presence of macrophages preventing proper T-cell activation (Engelhardt et al , 2012; Broz et al , 2014).”
PIK3CAH1047R induces multipotency and multi-lineage mammary tumours
Koren, S., Reavie, L., Couto, J. P., De Silva, D., Stadler, M. B., Roloff, T., Britschgi, A., Eichlisberger, T., Kohler, H., Aina, O., et al. (2015) · Nature · doi:10.1038/nature14669 · Cited by 327 · cited 1×
“Expression of Pik3ca H1047R was shown to evoke dedifferentiation of lineage-committed mammary epithelial cells into a multipotent stem - like state (Koren et al , 2015; Van Keymeulen et al , 2015).”
A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference
Premsrirut, P. K., Dow, L. E., Kim, S. Y., Camiolo, M., Malone, C. D., Miething, C., Scuoppo, C., Zuber, J., Dickins, R. A., Kogan, S. C., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.012 · Cited by 315
Targeted genomic rearrangements using CRISPR/Cas technology
Choi, P. S., & Meyerson, M. (2014) · Nature Communications · doi:10.1038/ncomms4728 · Cited by 309 · cited 1×
“…genetic alterations found in human tumors can now be rapidly introduced in the mouse germline, including (conditional) gene deletions (Wang et al , 2013; Yang et al , 2013), point mutations (Wang et al , 2013), and translocations (Blasco et al , 2014; Choi & Meyerson, 2014; Torres et al , 2014).”
Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 304 · cited 1×
“KB1P mice develop mammary tumors that mimic the histopathological features of human BRCA1 -mutated breast cancers as well as their hypersensitivity to platinum drugs and PARP inhibitors (Rottenberg et al , 2007, 2008).”
Self-citationHER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302 · cited 2×
“Cancer-associated fibroblasts (CAFs) Fibroblasts that reside in the tumor microenvironment.”
Conditional mouse models of sporadic cancer
Jonkers, J., & Berns, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc777 · Cited by 294 · cited 1×
“To circumvent this, more sophisticated mouse models are currently available that allow somatic inactivation of tumor suppressors or activation of (mutant) oncogenes in conditional GEMMs (Jonkers & Berns, 2002).”
Self-citationFichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M., & Merk, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0138 · Cited by 286 · cited 3×
“Therefore, PDTX models can be valuable tools to define personalized medicine as was demonstrated by preclinical drug screening in PDTX models of non-small-cell lung cancer (NSCLC) (Fichtner et al , 2008; Merk et al , 2009, 2011), breast cancer (Marangoni et al , 2007), melanoma (Kemper et al , 2015; Girotti et al , 20…”
Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling
Zuckermann, M., Hovestadt, V., Knobbe-Thomsen, C. B., Zapatka, M., Northcott, P. A., Schramm, K., Belic, J., Jones, D. T. W., Tschida, B., Moriarity, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8391 · Cited by 283 · cited 1×
“…non-germline models of hepatocellular carcinoma (Xue et al , 2014; Weber et al , 2015), lung cancer (Platt et al , 2014; Sa´nchez-Rivera et al , 2014), brain cancer (Zuckermann et al , 2015), pancreatic cancer (Chiou et al , 2015; Maresch et al , 2016), and breast cancer (Annunziato et al , 2016).”
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Rudalska, R., Dauch, D., Longerich, T., McJunkin, K., Wuestefeld, T., Kang, T.-W., Hohmeyer, A., Pesic, M., Leibold, J., von Thun, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3679 · Cited by 282 · cited 1×
“…have been successfully used to identify novel TSGs in mouse models of hepatocellular carcinoma and lymphoma (Hemann et al , 2003; Zender et al , 2008; Bric et al , 2009), and to identify genes involved in resistance to the tyrosine kinase inhibitor sorafenib in liver cancer (Rudalska et al , 2014).”
Chiou, S.-H., Winters, I. P., Wang, J., Naranjo, S., Dudgeon, C., Tamburini, F. B., Brady, J. J., Yang, D., Grüner, B. M., Chuang, C.-H., et al. (2015) · Genes & Development · doi:10.1101/gad.264861.115 · Cited by 264 · cited 1×
“…non-germline models of hepatocellular carcinoma (Xue et al , 2014; Weber et al , 2015), lung cancer (Platt et al , 2014; Sa´nchez-Rivera et al , 2014), brain cancer (Zuckermann et al , 2015), pancreatic cancer (Chiou et al , 2015; Maresch et al , 2016), and breast cancer (Annunziato et al , 2016).”
BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C., van der Heijden, I., van der Gulden, H., Wientjens, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.014 · Cited by 262 · cited 1×
“…breast cancer showed that, in contrast to Brca1 - null tumors, mammary tumors with expression of Brca1 alleles harboring mutations in the RING domain readily acquired resistance to DNA-damaging drugs due to residual activity of the RING-less BRCA1 protein (Drost et al , 2011, 2016).”
Self-citationLiu, P., Cheng, H., Santiago, S., Raeder, M., Zhang, F., Isabella, A., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2402 · Cited by 257 · cited 1×
“However, most tumors eventually recurred due to Met or Myc amplifications, indicating that these genetic lesions may induce resistance to PI3K inhibitors (Liu et al , 2011).”
Torres, R., Martin, M. C., Garcia, A., Cigudosa, J. C., Ramirez, J. C., & Rodriguez-Perales, S. (2014) · Nature Communications · doi:10.1038/ncomms4964 · Cited by 245 · cited 1×
“…genetic alterations found in human tumors can now be rapidly introduced in the mouse germline, including (conditional) gene deletions (Wang et al , 2013; Yang et al , 2013), point mutations (Wang et al , 2013), and translocations (Blasco et al , 2014; Choi & Meyerson, 2014; Torres et al , 2014).”
DuPage, M., Cheung, A. F., Mazumdar, C., Winslow, M. M., Bronson, R., Schmidt, L. M., Crowley, D., Chen, J., & Jacks, T. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.011 · Cited by 244 · cited 3×
“For example, the introduction of tumor-specific antigens in GEMMs with low immunogenic tumors, such as sarcomas and lung cancer, increased the immunogenicity of these tumors and resulted in a potent, but transient, anti-tumor T-cell response (DuPage et al , 2011, 2012).”
A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer
Schönhuber, N., Seidler, B., Schuck, K., Veltkamp, C., Schachtler, C., Zukowska, M., Eser, S., Feyerabend, T. B., Paul, M. C., Eser, P., et al. (2014) · Nature Medicine · doi:10.1038/nm.3646 · Cited by 237 · cited 1×
“Recently, an inducible dual-recombinase system was developed which combines Flp-FRT and Cre-loxP recombination systems, allowing sequential genetic manipulation of gene expression by two independent recombination systems (Scho¨nhuber et al , 2014).”
Girotti, M. R., Gremel, G., Lee, R., Galvani, E., Rothwell, D., Viros, A., Mandal, A. K., Lim, K. H. J., Saturno, G., Furney, S. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1336 · Cited by 231 · cited 1×
“…lung cancer (NSCLC) (Fichtner et al , 2008; Merk et al , 2009, 2011), breast cancer (Marangoni et al , 2007), melanoma (Kemper et al , 2015; Girotti et al , 2016), prostate cancer (Yoshida et al , 2005; Qu et al , 2014), and colorectal cancer (Bertotti et al , 2011, 2015; Bardelli et al ,…”
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Bou Reslan, H., Ho, C. C. K., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 215 · cited 1×
“Therapeutic responses of GEMMs to targeted therapy and conventional chemotherapy are very similar to those of human patients, as was assessed in GEMMs of Kras -mutant lung cancer and pancreatic cancer (Singh et al , 2010).”
Genetically Engineered Mouse Models in Cancer Research
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06004-5 · Cited by 206 · cited 1×
“By introducing mutations associated with a specific type of cancer, one can generate mouse models that closely mimic the histopathological, molecular, and clinical features of tumors in patients (Frese & Tuveson, 2007; Walrath et al , 2010).”
Simple and Rapid In Vivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology
Blasco, R. B., Karaca, E., Ambrogio, C., Cheong, T.-C., Karayol, E., Minero, V. G., Voena, C., & Chiarle, R. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.051 · Cited by 206 · cited 1×
“…genetic alterations found in human tumors can now be rapidly introduced in the mouse germline, including (conditional) gene deletions (Wang et al , 2013; Yang et al , 2013), point mutations (Wang et al , 2013), and translocations (Blasco et al , 2014; Choi & Meyerson, 2014; Torres et al , 2014).”
CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice
Weber, J., Öllinger, R., Friedrich, M., Ehmer, U., Barenboim, M., Steiger, K., Heid, I., Mueller, S., Maresch, R., Engleitner, T., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512392112 · Cited by 192 · cited 1×
“These efforts have led to a new generation of non-germline models of hepatocellular carcinoma (Xue et al , 2014; Weber et al , 2015), lung cancer (Platt et al , 2014; Sa´nchez-Rivera et al , 2014), brain cancer (Zuckermann et al , 2015), pancreatic cancer (Chiou et al , 2015; Maresch et al , 2016),…”
c-fos expression induces bone tumors in transgenic mice.
Rüther, U., Komitowski, D. D., Schubert, F., & Wagner, E. F. (1989) · PubMed · Cited by 184
Non-germline genetically engineered mouse models for translational cancer research
Heyer, J., Kwong, L. N., Lowe, S. W., & Chin, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2877 · Cited by 179 · cited 1×
“To speed up the generation of novel GEMMs of human cancer, embryonic stem cells (ESCs) can be genetically altered and used to produce cohorts of non-germline GEMMs (Heyer et al , 2010).”
Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kamoto, T., & Ogawa, O. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0817 · Cited by 178 · cited 1×
“…al , 2008; Merk et al , 2009, 2011), breast cancer (Marangoni et al , 2007), melanoma (Kemper et al , 2015; Girotti et al , 2016), prostate cancer (Yoshida et al , 2005; Qu et al , 2014), and colorectal cancer (Bertotti et al , 2011, 2015; Bardelli et al , 2013; Kavuri et al , 2015; Misale et al…”
Hanahan, D., Wagner, E. F., & Palmiter, R. D. (2007) · Genes & Development · doi:10.1101/gad.1583307 · Cited by 174 · cited 1×
“In the early 1980s, the first cloned cancer genes were introduced into the genome of transgenic mice, which were termed oncomice (Hanahan et al , 2007).”
Tissue-specific and reversible RNA interference in transgenic mice
Dickins, R. A., McJunkin, K., Hernando, E., Premsrirut, P. K., Krizhanovsky, V., Burgess, D. J., Kim, S. Y., Cordon-Cardo, C., Zender, L., Hannon, G. J., et al. (2007) · Nature Genetics · doi:10.1038/ng2045 · Cited by 174 · cited 1×
“Moreover, the development of systems for doxycycline-inducible shRNA expression in transgenic mice allows reversible expression of shRNAs in a time-and tissue-specific manner (Dickins et al , 2007; Premsrirut et al , 2011).”
Maresch, R., Mueller, S., Veltkamp, C., Öllinger, R., Friedrich, M., Heid, I., Steiger, K., Weber, J., Engleitner, T., Barenboim, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms10770 · Cited by 166 · cited 3×
“…non-germline models of hepatocellular carcinoma (Xue et al , 2014; Weber et al , 2015), lung cancer (Platt et al , 2014; Sa´nchez-Rivera et al , 2014), brain cancer (Zuckermann et al , 2015), pancreatic cancer (Chiou et al , 2015; Maresch et al , 2016), and breast cancer (Annunziato et al , 2016).”
Bric, A., Miething, C., Bialucha, C. U., Scuoppo, C., Zender, L., Krasnitz, A., Xuan, Z., Zuber, J., Wigler, M., Hicks, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.015 · Cited by 161 · cited 1×
“…have been successfully used to identify novel TSGs in mouse models of hepatocellular carcinoma and lymphoma (Hemann et al , 2003; Zender et al , 2008; Bric et al , 2009), and to identify genes involved in resistance to the tyrosine kinase inhibitor sorafenib in liver cancer (Rudalska et al , 2014).”
Lunardi, A., Ala, U., Epping, M. T., Salmena, L., Clohessy, J. G., Webster, K. A., Wang, G., Mazzucchelli, R., Bianconi, M., Stack, E. C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2650 · Cited by 144 · cited 1×
“This strategy was successfully used to identify genetic determinants of androgen deprivation resistance in prostate cancer, as well as novel combination therapies to overcome castration resistance (Lunardi et al , 2013).”
Annunziato, S., Kas, S. M., Nethe, M., Yücel, H., Del Bravo, J., Pritchard, C., Bin Ali, R., van Gerwen, B., Siteur, B., Drenth, A. P., et al. (2016) · Genes & Development · doi:10.1101/gad.279190.116 · Cited by 144 · cited 2×
“…non-germline models of hepatocellular carcinoma (Xue et al , 2014; Weber et al , 2015), lung cancer (Platt et al , 2014; Sa´nchez-Rivera et al , 2014), brain cancer (Zuckermann et al , 2015), pancreatic cancer (Chiou et al , 2015; Maresch et al , 2016), and breast cancer (Annunziato et al , 2016).”
Self-citationDevelopment trends for new cancer therapeutics and vaccines
Reichert, J. M., & Wenger, J. B. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.09.003 · Cited by 143 · cited 1×
“Despite successful validation of novel anti-cancer therapies in conventional preclinical mouse models based on xenotransplantation of established human cancer cell lines or allotransplantation of mouse tumor cell lines, the majority of the phase 3 clinical trials fail (Reichert & Wenger, 2008).”
Mouse hospital and co-clinical trial project—from bench to bedside
Clohessy, J. G., & Pandolfi, P. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.62 · Cited by 141 · cited 1×
“Recently, a “co-clinical trial” paradigm has been developed in which preclinical trials in GEMMs are run in parallel with human clinical trials to predict therapeutic response (Clohessy & Pandolfi, 2015).”
Kemper, K., Krijgsman, O., Cornelissen‐Steijger, P., Shahrabi, A., Weeber, F., Song, J., Kuilman, T., Vis, D. J., Wessels, L. F., Voest, E. E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404914 · Cited by 140 · cited 2×
“Cancer-associated fibroblasts (CAFs) Fibroblasts that reside in the tumor microenvironment.”
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Drost, R., Dhillon, K. K., van der Gulden, H., van der Heijden, I., Brandsma, I., Cruz, C., Chondronasiou, D., Castroviejo-Bermejo, M., Boon, U., Schut, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci70196 · Cited by 139 · cited 1×
“…breast cancer showed that, in contrast to Brca1 - null tumors, mammary tumors with expression of Brca1 alleles harboring mutations in the RING domain readily acquired resistance to DNA-damaging drugs due to residual activity of the RING-less BRCA1 protein (Drost et al , 2011, 2016).”
Self-citationBovine papillomavirus genome elicits skin tumours in transgenic mice
Lacey, M., Alpert, S., & Hanahan, D. (1986) · Nature · doi:10.1038/322609a0 · Cited by 130 · cited 1×
“…first oncomice led to great excitement in the cancer research community as they provided unambiguous proof for the hypothesis that oncogene expression in normal cells could lead to tumor formation (Brinster et al , 1984; Hanahan, 1985; Lacey et al , 1986; Sinn et al , 1987; Ru¨ther et al , 1989).”
Henneman, L., van Miltenburg, M. H., Michalak, E. M., Braumuller, T. M., Jaspers, J. E., Drenth, A. P., de Korte-Grimmerink, R., Gogola, E., Szuhai, K., Schlicker, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500223112 · Cited by 126 · cited 2×
“Preclinical studies in KB1P mice revealed several mechanisms of resistance, such as elevated levels of drug efflux transporters and restoration of homologous recombination (Rottenberg et al , 2008; Jaspers et al , 2013; Henneman et al , 2015; Xu et al , 2015).”
Self-citationVertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
Misale, S., Bozic, I., Tong, J., Peraza-Penton, A., Lallo, A., Baldi, F., Lin, K. H., Truini, M., Trusolino, L., Bertotti, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9305 · Cited by 122 · cited 1×
“…2011), breast cancer (Marangoni et al , 2007), melanoma (Kemper et al , 2015; Girotti et al , 2016), prostate cancer (Yoshida et al , 2005; Qu et al , 2014), and colorectal cancer (Bertotti et al , 2011, 2015; Bardelli et al , 2013; Kavuri et al , 2015; Misale et al , 2015; Zanella et al , 2015).”
Holzapfel, B. M., Wagner, F., Thibaudeau, L., Lévesque, J.-P., & Hutmacher, D. W. (2015) · Stem Cells · doi:10.1002/stem.1978 · Cited by 119 · cited 2×
“Cancer-associated fibroblasts (CAFs) Fibroblasts that reside in the tumor microenvironment.”
Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010445 · Cited by 117 · cited 2×
“Cancer-associated fibroblasts (CAFs) Fibroblasts that reside in the tumor microenvironment.”
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation
Braun, C. J., Bruno, P. M., Horlbeck, M. A., Gilbert, L. A., Weissman, J. S., & Hemann, M. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600582113 · Cited by 101 · cited 1×
“To this end, CRISPRa-based systems may be used to activate transcription of target genes (Braun et al , 2016).”
Rapid target gene validation in complex cancer mouse models using re‐derived embryonic stem cells
Huijbers, I. J., Ali, R. B., Pritchard, C. E. J., Cozijnsen, M., Kwon, M., Proost, N., Song, J., de Vries, H., Badhai, J., Sutherland, K., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303297 · Cited by 94 · cited 1×
“These GEMM-derived ESCs can be used for rapid introduction of additional genetic modifications and subsequent production of chimeric mice that show the same characteristics as the established GEMM but now contain the additional genetic modification (Huijbers et al , 2011, 2014).”
Self-citationDuPage, M., & Jacks, T. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.005 · Cited by 91 · cited 1×
“Thus, these models can aid ongoing and future research to unravel the complex mechanisms underlying immune evasion (DuPage & Jacks, 2013), and may ultimately lead to novel (combination) strategies to improve cancer immunotherapy.”
Patient-derived breast tumor xenografts facilitating personalized cancer therapy
Landis, M. D., Lehmann, B. D., Pietenpol, J. A., & Chang, J. C. (2013) · Breast Cancer Research · doi:10.1186/bcr3355 · Cited by 91 · cited 1×
“Unfortunately, a major obstacle of PDTX modeling is the disappointing take rate of various tumor types, such as estrogen receptor-positive breast cancer and prostate cancer (Landis et al , 2013; Lawrence et al , 2015).”
Engineering humanized mice for improved hematopoietic reconstitution
Drake, A. C., Chen, Q., & Chen, J. (2012) · Cellular & Molecular Immunology · doi:10.1038/cmi.2012.6 · Cited by 84 · cited 1×
“Current efforts to generate humanized mice by engrafting immunodeficient mice with human CD34 + hematopoietic stem cells or precursor cells have shown remarkable progress (Drake et al , 2012; Holzapfel et al , 2015).”
A Preclinical Mouse Model of Invasive Lobular Breast Cancer Metastasis
Doornebal, C. W., Klarenbeek, S., Braumuller, T. M., Klijn, C. N., Ciampricotti, M., Hau, C.-S., Hollmann, M. W., Jonkers, J., & de Visser, K. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-11-4208 · Cited by 71 · cited 1×
“This problem can be overcome by orthotopic transplantation of GEMM-derived tumor fragments — which maintain the intratumoral heterogeneity of donor tumors — followed by surgical resection, allowing the development of clinically overt metastatic disease (Doornebal et al , 2013).”
Self-citationMinimal residual disease in cancer therapy – Small things make all the difference
Blatter, S., & Rottenberg, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.003 · Cited by 65 · cited 1×
“…clear that therapy response and resistance is not only influenced by tumor cell-intrinsic factors but also by stromal factors such as fibroblasts and immune cells (Farmer et al , 2009; DeNardo et al , 2011; Shree et al , 2011; Acharyya et al , 2012; Nakasone et al , 2012; Boelens et al , 2014).”
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence
Kottke, T. J., Boisgerault, N., Díaz, R. M., Donnelly, O., Rommelfanger, D. M., Pulido, J. S., Thompson, J., Mukhopadhyay, D., Kaspar, R. L., Coffey, M. C., et al. (2013) · Nature Medicine · doi:10.1038/nm.3397 · Cited by 64 · cited 1×
“…apparently successful treatments, small numbers of drug-tolerant tumor cells can survive and remain dormant for extended periods of time and eventually relapse to form recurrent disease that can be phenotypically different from the original tumor (Kottke et al , 2013; Blatter & Rottenberg, 2015).”
Scheer, N., Kapelyukh, Y., McEwan, J., Beuger, V., Stanley, L. A., Rode, A., & Wolf, C. R. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.075192 · Cited by 61 · cited 1×
“…of novel biomarkers, and development of optimal combination therapies, culminating in improved cancer patient care. enzyme — which is involved in drug metabolism in the liver — is highly variable between species, an issue that could be overcome by humanizing mice (Scheer et al , 2012).”
Merk, J., Rolff, J., Becker, M., Leschber, G., & Fichtner, I. (2009) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2009.03.054 · Cited by 59 · cited 1×
“…personalized medicine as was demonstrated by preclinical drug screening in PDTX models of non-small-cell lung cancer (NSCLC) (Fichtner et al , 2008; Merk et al , 2009, 2011), breast cancer (Marangoni et al , 2007), melanoma (Kemper et al , 2015; Girotti et al , 2016), prostate cancer (Yoshida et…”
Generation of targeted mouse mutants by embryo microinjection of TALEN mRNA
Wefers, B., Panda, S. K., Ortiz, O., Brandl, C., Hensler, S., Hansen, J., Wurst, W., & Kühn, R. (2013) · Nature Protocols · doi:10.1038/nprot.2013.142 · Cited by 58 · cited 1×
“…the latter approach, Dow et al Genome editing using CRISPR/Cas 9 technology In the past decades, additional approaches for genome editing have been developed such as Zinc-finger nucleases (ZFNs) and transcrip-tion-activator-like effector nucleases (TALENs) (Li et al , 2011; Wefers et al , 2013).”
Garbe, A. I., Vermeer, B., Gamrekelashvili, J., Wasielewski, R. V., Greten, F. R., Westendorf, A. M., Buer, J., Schmid, R. M., Manns, M. P., Korangy, F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2383 · Cited by 42 · cited 2×
“…tumor cells in immunodeficient mice resulted in rapid tumor growth, while wild-type mice rejected these tumors (Willimsky & Blankenstein, 2005; Garbe et al , 2006; DuPage et al , 2011), demonstrating that the cancer cells did not lose their immunogenicity and T cells are still able to…”
Merk, J., Rolff, J., Dorn, C., Leschber, G., & Fichtner, I. (2011) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2011.02.010 · Cited by 41 · cited 1×
“…personalized medicine as was demonstrated by preclinical drug screening in PDTX models of non-small-cell lung cancer (NSCLC) (Fichtner et al , 2008; Merk et al , 2009, 2011), breast cancer (Marangoni et al , 2007), melanoma (Kemper et al , 2015; Girotti et al , 2016), prostate cancer (Yoshida et…”
Lawrence, M. G., Pook, D. W., Wang, H., Porter, L. H., Frydenberg, M., Kourambas, J., Appu, S., Poole, C., Beardsley, E. K., Ryan, A., et al. (2015) · The Prostate · doi:10.1002/pros.23039 · Cited by 40 · cited 1×
“Unfortunately, a major obstacle of PDTX modeling is the disappointing take rate of various tumor types, such as estrogen receptor-positive breast cancer and prostate cancer (Landis et al , 2013; Lawrence et al , 2015).”
Huijbers, I. J., Krimpenfort, P., Berns, A. J. M., & Jonkers, J. (2011) · BioEssays · doi:10.1002/bies.201100018 · Cited by 40 · cited 1×
“These GEMM-derived ESCs can be used for rapid introduction of additional genetic modifications and subsequent production of chimeric mice that show the same characteristics as the established GEMM but now contain the additional genetic modification (Huijbers et al , 2011, 2014).”
Self-citationQu, S., Wang, K., Xue, H., Wang, Y., Wu, R., Liu, C., Gao, A. C., Gout, P. W., Collins, C. C., & Wang, Y. Z. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.004 · Cited by 34 · cited 2×
“Cancer-associated fibroblasts (CAFs) Fibroblasts that reside in the tumor microenvironment.”
Finlay, C. A. (1992) · BioEssays · doi:10.1002/bies.950140811 · Cited by 24 · cited 1×
“With the development of gene-targeting technology in 1992, also cancer predisposition in tumor suppressor gene (TSG) knockout mice could be studied (Finlay, 1992).”
Cited by
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
“However, next-generation GEMM are designed to more accurately mimic human cancers, including ITH (Kersten et al., 2017).”
MethodGenetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
“Also, in vivo RNAi technology, particularly inducible shRNA expression in transgenic mice, enables time- and tissuespecific control of silencing of gene expression and affords an alternative gene inactivation approach to identify novel genes involved in tumor suppression or therapy resistance (Kersten et al. 2017).”
BackgroundCancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589
“For these reasons, mechanistic studies in relevant GEMMs that mimic the development, heterogeneity and progression of human tumors in an immune-proficient setting are key to understand how cancer cell-intrinsic properties can dictate the tumor immune landscape (Kersten et al., 2017).”
Background
Metadata
- Authors
- Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Jonkers, Jos
- Venue
- EMBO Molecular Medicine
- Published
- 2016-12-27
- Volume
- 9
- Issue
- 2
- Pages
- 137-153
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC5286388
- OpenAlex
- W2563661701
- Semantic Scholar
- 157896602a8b1e213e59d905c681094819be5e34
- Cited by
- 502
- References
- 168
- Citations by year
- 2026: 53 · 2025: 47 · 2024: 52 · 2023: 69 · 2022: 75 · 2021: 61 · 2020: 59 · 2019: 39 · 2018: 32 · 2017: 13 · 2016: 2
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- other-oa
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Dutch Cancer Society (5220, 6532, 7048, 7589, 7835, 7877)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (93512009, 91814643, National Roadmap grant for Large‐scale Research Facilities)
- Worldwide Cancer Research (14‐0288)
- European Union Seventh Framework Program (260791, 312325, MCA‐ITN 317445)
- European Research Council (319661, 615300)
- Beug Foundation for Metastasis Research
- EMBO Young Investigator
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- genetically engineered mouse models, cancer research, tumor microenvironment, metastasis, preclinical cancer models, drug target validation, drug resistance, tumor heterogeneity, translational oncology
- MeSH terms
- Animals, Disease Models, Animal, Humans, Medical Oncology, Neoplasms, Animals, Genetically Modified, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.